Discover how AI chatbots are reshaping weight-loss planning with precision and variety, yet face challenges in balancing macronutrients for optimal health.
Novartis to seek approvals in two rare kidney diseases after positive Phase 3 trials
Novartis is building out its rare kidney disease portfolio with two batches of Phase 3 data at the European Renal Association conference, touting positive results